“PhasED-Seq detected MRD at levels below 1 ppm and was associated with significantly better outcomes, revealing potential benefits of adjuvant therapy in patients with MRD+. This suggests that ultrasensitive MRD detection is promising for use in risk-adapted trials in early-stage NSCLC,” Dr James M. Isbell, MD, MSCI, and colleagues wrote in the abstract of their poster presentation.
“Translation of ctDNA MRD in NSCLC has been hampered by suboptimal sensitivity of 1st-generation assays. Here, we explore how improvements in analytical sensitivity can drive improved clinical sensitivity for MRD after surgery in NSCLC,” the researchers added.
To investigate MRD kinetics, Dr Isbell and his colleagues analysed longitudinal ctDNA in early-stage NSCLC using data from the TRACERx study. The researchers generated patient-specific mathematical models to predict MRD levels at the postsurgical landmark and estimate the impact of an assay’s 95% detection limit (LOD95) on clinical sensitivity.
Dr Isbell and his colleagues performed tumor-informed ctDNA testing using a single nucleotide variation (SNV) -based assay, Cancer Personalized Profiling by deep Sequencing (CAPP-Seq), and a phased variant-based assay, Phased variant Enrichment and Detection by Sequencing (PhasED-Seq), Foresight Diagnostics, on 269 samples from 46 patients. The researchers also evaluated how well MRD predicted patient outcomes at the landmark time point and the effect of adjuvant treatment.
The researchers assessed ctDNA MRD dynamics in 23 patients with 3 or more consecutive samples with detectable ctDNA without intervening therapy. MRD kinetics correlated strongly with exponential growth, with a median ctDNA doubling time of 51 days. Extrapolating MRD levels to the postsurgical landmark predicted that improving MRD assay LOD95 from 100 ppm (0.01%) to 1 ppm could more than double clinical sensitivity.
Dr Isbell and his colleagues then used 2 essays to evaluate 46 NSCLC cases. The median LOD95 was 1 ppm for PhasED-Seq and 84 ppm for CAPP-Seq. Twelve cases were MRD+ by PhasED-Seq, and all of them recurred (100%), with MRD levels as low as 0.19 ppm. By contrast, 6 cases were MRD+ by the SNV-based approach, and 5 (83%) recurred. PhasED-Seq had a higher clinical sensitivity than the SNV-based method (12/18, 67% vs 5/18, 28%; P=0.022).
Kaplan Meier analysis for freedom from recurrence showed significantly poorer outcomes for patients with detectable MRD regardless of the method used, but outcomes were better stratified using PhasED-Seq (HR, 3.1 versus 11.4).
Patients with MRD- after surgery, according to both assays, had similar outcomes regardless of adjuvant therapy (chemotherapy, radiotherapy, or both). However, patients with MRD+ by PhasED-Seq who received adjuvant therapy had significantly better outcomes than those who did not (HR 8.2; P=0.00035). No similar benefit for adjuvant therapy was found with the SNV-based assay. Using PhasED-Seq, 80% (4/5) of patients with MRD+ who received adjuvant therapy cleared their MRD, compared with 0% (0/3) who did not have adjuvant treatment.
Source: meetings.asco.org/abstracts-presentations/232835
Originally Published By Physician’s Weekly. Reused by Medicom Medical Publishers with permission.
©2024 Physician’s Weekly. All rights reserved. No works may be reproduced without expressed written consent from Physician’s Weekly. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by Physician’s Weekly.
Posted on
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com